Axogen develops processed nerve allografts and tissue-engineered biologics for peripheral nerve repair and regeneration. The company is midway through an enterprise-wide digital transformation—deploying Tulip MES integration, moving to cloud infrastructure (Azure, Dynamics 365, Power BI), and hardening security posture—while simultaneously scaling sales operations and navigating multi-market regulatory compliance. The hiring mix (sales-heavy with solid engineering and manufacturing coverage) reflects dual pressure: commercializing a maturing product portfolio and building internal systems to support growth.
Axogen is a publicly traded medical device and regenerative medicine company focused on restoring peripheral nerve function through surgical repair solutions. The company manufactures processed nerve allografts and biologics for surgeons and healthcare providers treating traumatic nerve injuries and surgical nerve discontinuities. Headquartered in Alachua, Florida with 201–500 employees, Axogen operates across the United States, United Kingdom, and Peru. Core challenges center on expanding surgeon and hospital adoption, building awareness among referring physicians and patients, managing regulatory compliance across multiple geographies, and scaling internal sales and operational infrastructure to support revenue growth.
Axogen develops processed nerve allografts and tissue-engineered biologics for peripheral nerve repair and regeneration in surgical settings.
Axogen is headquartered in Alachua, Florida, and employs 201–500 people across operations in the United States, United Kingdom, and Peru.
Axogen is integrating Tulip MES for manufacturing, migrating to Microsoft Azure and Dynamics 365 for enterprise systems, and deploying Power BI for analytics as part of a broader digital transformation.
Other companies in the same industry, closest in size